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OPTIMIZING PRESERVATION OF UMBILICAL VEIN SEGMENTS FOR USE  
 
AS AUTOLOGOUS SHUNTS IN NEONATAL CARDIAC REPAIR  
 
KIMBERLY RICH 
ABSTRACT 
Introduction: The Modified Blalock Taussig (BT) shunt is the most common 
palliative procedure in neonatal cardiac repair to secure pulmonary blood flow (3-
6) despite high mortality and morbidity rates of 4-14% (3,5) and 9-18% (4,5) 
respectively. The high risk of thrombosis and stenosis associated with the 
polytetrafluoroethylene (PTFE) material that is currently used for BT shunts 
significantly contributes to these high mortality and morbidity rates. Thrombosis 
and stenosis occur in 3-12% of patients (1,5), primarily due to the lack of 
endothelium of the synthetic PTFE graft. This study hypothesizes that a 
preserved autologous umbilical vein could be a feasible replacement for the 
PTFE graft. Experiments were performed to examine and optimize preservation 
methods of umbilical veins for use as BT shunts.   
Methods: Umbilical cords (n=45) were collected from healthy neonates and 
umbilical vein segments were preserved in either static (n=145) or flow conditions 
(n=84) for 7 days or 14 days in varying media. Samples of each vein were 
collected at time of harvest (Day 0) and at the end of culture and compared by 
burst pressure, histopathology, platelet adhesion and scanning electron 
microscopy (SEM).  
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Results: Burst pressure strength of veins from Day 0 to up to two weeks of 
preservation did not significantly differ (431 ± 229 mmHg vs 438 ±  244 mmHg). 
Overall histology demonstrated an improved morphology in endothelial and 
medial layers of the segments preserved in flow culture with UW + 5% HPL for 7 
days. Platelet adhesion testing demonstrated significantly less platelet 
attachment in flow samples compared to static, indicating less endothelial injury. 
SEM showed greater cellular flow-alignment and consistency of the endothelium 
in flow samples.  
Conclusion: Flow culture utilizing UW plus 5% HPL adequately preserves 
morphology and function of the endothelium. Preserved autologous umbilical 
veins stand as a viable option to replace the current PTFE graft used for BT 
shunts due to the presence of an endothelium.  
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INTRODUCTION 
 
Modified Blalock-Taussig (BT) shunts are grafts that are sutured between 
systemic and pulmonary artery circulation in order to redirect systemic blood flow 
to the lungs (1) (Figure 1). BT shunts are used to temporarily relieve cyanosis in 
neonates and infants with congenital heart defects, including right-sided 
obstructive cardiac defects (1). In these cases, the blood reaching systemic 
circulation is not properly oxygenated, as the heart defect does not allow 
sufficient amounts of blood to reach the lungs for oxygenation. With placement of 
the BT shunt, some systemic blood can be routed directly to the pulmonary artery 
and therefore to the lungs and back into systemic circulation, increasing the 
amount of oxygenated blood reaching tissues and organs. With advancements of 
fetal ultrasound technology, congenital heart defects can be detected in-utero 
prior to birth in order to properly prepare for intervention after delivery. Detection 
rates are as high as 59.7% (2). Our study focuses mainly on patients with 
triscuspid atresia (TA) or pulmonary atresia with intact ventricular septum 
(PA/IVS), as patients with these diagnoses will most likely need a BT shunt as 
part of their neonatal repair.  
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Figure 1. BT shunt: subclavian artery to pulmonary artery (7) 
 
To date, BT shunts are the most used palliative surgeries that are crucial 
to securing pulmonary blood flow for patients until they are the appropriate age 
and weight for the next stage of care (3-6). However, risks of BT shunts in this 
interstage period remain high. Risks include excessive volume load, pulmonary 
over circulation (POC), acute thrombosis and shunt occlusion (6). In some cases 
this leads to reintervention with balloon dilation or stent implantation to help clear 
the blockage or even surgery if necessary (3,7). In extreme cases, patients may 
need to be put on extra corporeal membrane oxygenation (ECMO) 
postoperatively (3,4) as a result of acute cardiac failure or acute hypoxemia due 
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to surgical or shunt complications (7). Patients who require ECMO 
postoperatively are at a higher risk of mortality, as ECMO increases the risk of 
bleeding, coagulopathy and thrombosis (7). Two studies showed this mortality 
rate to be 64% (4) and 75% (8). Overall, in-hospital mortality for this procedure 
remains between 4-14% (3,5), with post discharge mortality ranging from 9-11% 
(4, 5). Morbidity rates are high as well ranging from 9 to 18% (4,5). However, 
despite the high risks of BT shunts they still play a significant role in managing 
cyanotic heart disease in children (9).  
The typical material used for BT shunts is a synthetic 
polytetrafluoroethylene (PTFE) graft. Other options have been explored in small 
series including human saphenous vein grafts (SVG) (6,10) and fixed bovine 
internal mammary artery grafts (11), both of which are stented down to the 
appropriate shunt diameter prior to implantation. Determining shunt diameter 
depends mainly on the weight of the child (3,5,12-14). The use of glutaraldehyde-
tanned human umbilical vein grafts soaked in saline prior to implantation has also 
been reported (9). Some disadvantages of PTFE include serous or blood leakage 
from suture lines and late occurring infectious complications (15,16). The most 
prominent issue of PTFE grafts is related to its electronegative surface (1) and 
lack of appropriate endothelium, both of which support the activation of 
coagulation pathways leading to increased platelet adhesion and thrombosis. 
Although outcomes of other grafts have been favorable, PTFE still remains the 
material of choice for BT shunts.  
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Undergoing surgery causes a hypercoaguable state both during surgery 
and postoperatively due to endothelial injury to the vessels involved (1). This, in 
combination with the lack of endothelium of BT shunts and other variables 
including shunt size (3,7,14) and pulmonary artery size (1) can increase the risk 
of thrombosis or stenosis in these shunts. Studies describe shunt thrombosis and 
stenosis as major issues related to unfavorable outcomes with this procedure 
(3,5,6), as thrombotic occlusion can occur within hours after the surgery or before 
hospital discharge resulting in loss of pulmonary blood flow and subsequent 
hypoxia or cardiac arrest (1). In one study, shunt thrombosis occurred in 9.2% of 
patients at a median of 3 hours postoperatively, leading to 33% of in-hospital 
deaths (5). Rates of shunt stenosis remain high, with 64% of BT shunts having 
greater than 25% narrowing and 21% having greater than 50% at time of 
takedown (17). Overall, BT shunt thrombosis/stenosis occurs in 3-12% of 
patients (1,5). Thrombotic complications are important factors contributing to 
mortality and morbidity in BT shunt procedures, and have yet to be effectively 
prevented with any of the current anticoagulation therapies (5).  
 
Background 
The lack of endothelium in PTFE grafts causes an inflammatory response 
leading to increased platelet attachment and subsequent thrombosis and 
stenosis. Utilizing a graft with a functional endothelium would help to decrease 
these risks associated with the BT shunt procedure. It is hypothesized that 
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preserving an autologous umbilical vein as a replacement for the PTFE graft 
would maintain the presence and function of the endothelium, thus decreasing 
activation of coagulation pathways and platelet interaction at the endothelium. 
Endothelial injury causes platelets to attach to the exposed basement membrane 
and underlying collagen fibers and release factors that activate smooth muscle 
cells to proliferate, causing intimal hyperplasia, thickening and stiffening of the 
vessel wall, and therefore stenosis (18,19). Thus, this study focuses on 
optimizing preservation of the endothelium of umbilical veins in order to decrease 
inflammatory pathways leading to thrombosis and stenosis.  
Utilizing an autologous fetal umbilical vein as a BT shunt is feasible partly 
because of fetal ultrasound technology. This allows detection and diagnosis of 
the heart defect and appropriate planning for birth and intervention for care, thus 
allowing collection of the umbilical cord at the time of delivery. Parents will be 
consented prior to birth in order to collect, dissect and preserve the fetal umbilical 
cord until implantation into the neonate. After collection the umbilical vein will be 
dissected from the cord in a sterile field and preserved in a precise combination 
of media and growth factors until the neonate is stable enough to undergo 
surgery, typically between 3 to 7 days. At the time of implantation, the vein will be 
sized according to the neonate’s physiology and surgeon’s discretion (1,5), and 
stented down to 3-4mm in diameter (1,3,5,7,14,15,20).   
Currently the main concern of organ transplantation is utilizing the 
appropriate preservation technique in order to decrease damage during the 
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ischemic time between removal of the organ and subsequent implantation (21, 
22). Cold preservation (0-4°C) has been utilized for kidneys and livers based on 
the effect of hypothermia to slow cellular metabolism and the production of toxic 
substances (21). For kidneys, the most common preservation techniques include 
cold static storage and hypothermic perfusion (21). Our study aimed to compare 
both static and flow preservation of umbilical vein segments.  
To optimize preservation of umbilical vein segments, media type, culture 
conditions, and length of culture were tested. Determining a precise media 
combination for preservation was the initial step in this study. Previous literature 
utilizing saphenous vein allografts as BT shunts cited preserving the grafts in 
both Hank’s solution and with cryopreservation (15). Physiological saline and 
heparinized autologous blood have also been used to preserve coronary artery 
bypass grafts, but saline caused endothelial damage and decreased graft 
patency compared to blood (20). With the focus on maintaining growth and 
function of endothelial cells, an endothelial cell growth media, EGM-2MV (EGM) 
(Lonza, Allendale, NJ) with Fetal Bovine Serum (FBS) was first tested. FBS is the 
standard serum added to media for culturing cells, functioning to stimulate cell 
proliferation and provide factors needed to maintain pH or inhibit toxic molecules 
(12). Early umbilical vein samples preserved statically in EGM with 2% FBS 
(n=11) for 13-26 days at 37°C did not have adequate endothelial and vascular 
wall preservation, thus preservation methods were switched to cold culture at 
4°C (23).  
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In cold preservation, EGM with FBS was tested in static culture, and University of 
Wisconsin (UW) preservation solution (Preservation Solutions, Golden, CO) with 
and without serum was tested in static and flow culture. UW is the most 
used preservation solution for livers, kidneys, and pancreases (24). It has been 
shown to improve the quality of organ function, increase the duration of 
preservation by cold static storage (25,26) and is considered the golden standard 
for preservation media (24).  
Human Platelet Lysate (HPL) (Cook Medical, Bloomington, IN or Compass 
Biomedical, Cleveland, OH) was utilized as a replacement for FBS. Platelets 
contain bioactive molecules and growth factors that are released when they are 
destroyed (12). These biomolecules promote greater cell proliferation in 
comparison to FBS, as seen in multiple studies observing a substantial increase 
in expansion of mesenchymal stem cells in culture when utilizing HPL versus 
FBS (12,27-31).  
Plain UW with antibiotics was tested in static cultures, UW with HPL in static and 
flow cultures and EGM with HPL in static and flow cultures. UW with HPL was 
used for the majority of this study, but further experiments varying length of 
culture and concentration of HPL were tested and are ongoing. 
The following tests were conducted in order to optimize preservation of human 
umbilical vein for potential use as a replacement for the current BT shunt. 
Optimizing preservation will help to maintain the function of the endothelium in 
order to reduce the risk of thrombosis and stenosis in these shunts. We 
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hypothesize that preservation utilizing flow culture will better maintain endothelial 
function and morphology compared to static preservation (23). 
	 9	
METHODS 
* All supplies bought from Sigma Aldrich unless otherwise noted.  
 
 
I. Collection of Umbilical Cord  
 
 
Umbilical cords (n=45) were collected from healthy neonates at Brigham and 
Women’s Hospital (Boston, MA) per IRB approval. At the time of delivery, cords 
were placed in a container with sterile UW solution with penicillin g potassium 
salt and gentamicin amphotericin (Life Technologies, Carlsbad, CA or Zen Bio, 
Research Triangle Park, NC). Umbilical cords ranging from 6 – 50cm in length 
(20.6 cm ± 9.98) were stored at 4°C until dissection up to 24 hours after delivery.   
 
II. Dissection of Umbilical Vein  
 
 
A sterile field was set up in a vented hood for dissection. Umbilical veins were 
dissected from the cords and the diameters (5.46 mm ± 0.76) were measured 
using Hegar dilators, ranging from 4-7mm. After dissection, 1 cm segments were 
placed in either Optimal Cutting Temperature (OCT) freezing solution, or in 10% 
formalin or 4% paraformaldehyde (PFA). OCT samples were stored at -80°C, 
and the 10% formalin and 4% PFA samples were stored at room temperature. 
These were labeled as “fresh” samples (n=61), indicating a segment that was 
collected at time point Day 0. The remaining vein segments were preserved in 
either static or flow conditions.  
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III. Preservation Media 
 
UW versus Endothelial Cell Culture Media  
EGM media with varying concentrations of FBS (5%, 10%, 20%) were tested in 
static conditions at 4°C. UW was tested without HPL in static conditions, and with 
HPL in both static and flow conditions. Flow culture with UW plus HPL varied in 
concentrations of HPL (5%, 10%, 20%). HPL was also added to EGM at varying 
concentrations (5%, 10%) in flow culture only.  
 
Human Platelet Lysate (HPL) versus Fetal Bovine Serum (FBS) 
FBS was first used as a serum supplement for EGM preservation media. With 
results demonstrating insufficient preservation of the endothelium with this media 
combination, UW and HPL were then utilized as the primary preservation solution 
and supplementary growth serum.  
 
IV. Static Preservation vs. Flow Preservation 
 
Static conditions involve an organ resting in preservation media on a shaker table 
at low speed, whereas flow conditions involve the circulation of media through an 
organ’s vessels to increase surface area contact. Both static and flow conditions 
were tested to preserve umbilical vein segments. Table A summarizes the vein 
totals in each condition tested. 
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Table A. Vein Totals 
 Acute Static Flow 
Total veins 38 23 32 
Total 
segments 61 145 84 
7-day culture  n/a 
89 segments from 
23 veins 
66 segments from 
28 veins 
14-day culture  n/a 
55 segments from 
8 veins 
13 segments from 
4 veins 
EBM+5% 
FBS  n/a 
3 segments from 1 
vein n/a 
EBM+ 10% 
FBS  n/a 
3 segments from 1 
vein n/a 
EBM+ 20% 
FBS n/a 
21 segments from 
2 veins n/a 
EBM+ 5% 
HPL n/a 
15 segments from 
3 veins 
2 segments from 1 
vein 
EBM+ 10% 
HPL n/a 
3 segments from 1 
vein 
2 segments from 1 
vein 
UW n/a 
32 segments from 
7 veins n/a 
UW+ 5% HPL n/a 
61 segments from 
19 veins 
75 segments from 
28 veins 
UW+ 10% 
HPL n/a n/a 
5 segments from 2 
veins 
UW + 20% 
HPL n/a n/a 
2 segments from 1 
vein 
 
Static Preservation 
Veins ranging from 0.5 – 4 cm in length were placed in a container with either 
50ml or 100ml of media per cm of vein. Media tested included EGM with FBS, 
EGM with HPL, and UW with or without HPL. A 0.22um filter was attached to the 
lid of the container in order to promote ventilation. The containers were placed on 
a shaker table at low speed at 4°C for either 7 days or 14 days (Figure 2). At the 
endpoint of Day 7 or Day 14, 0.5-1cm segments were collected from the middle 
of the veins and placed in either OCT solution or 4% PFA / 10% formalin and 
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scanning electron microscopy (SEM) fixative. Samples in SEM fixative were 
stored at room temperature.  
 
Figure 2. Static culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow Preservation: BioRx 1 
The flow condition was tested in three different methods at 4°C. At first, a novel 
bioreactor (BioRx 1) was designed, which utilized a roller pump (MasterFlex, 
Gelsenkirchen, Germany) to push media through the tubing and veins (Figure 3). 
Two reservoirs were placed in the system; one for holding the circulating media, 
and one for holding the umbilical vein segments, as seen in Figure 4. Both 
containers had a 0.22um-filtered lid for ventilation. 750ml to 1000ml of either 
EBM plus HPL or UW plus HPL media were used to culture veins for 7 days. 
Pump settings were set to maintain a flow in the umbilical veins around 50ml/min 
per vein and shear stress of ~1.76 dynes, with up to four segments tested at 
once. Flow segments in BioRx 1 (n=57) ranged from 4- 5 cm in length. At 
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endpoint Day 7, 0.5-1cm segments were collected from the middle of the veins 
and placed in either OCT solution or 4% PFA / 10% formalin and SEM fixative.  
 
Figure 3. BioRx 1 setup (23)    Figure 4. BioRx 1 culture (23) 
 
 
 
 
Flow Preservation: Lifeport  
The second flow condition tested was the FDA approved Lifeport Kidney 
Transporter System (Organ Recovery Systems, Itasca, IL) seen in Figure 5. This 
flow system differs from BioRx 1 in that the reservoir holding the veins also 
contains the circulating media (Figure 6). This design certainly ensures that both 
the media surrounding the vein segments and the media running through the 
segments are perpetually circulated. Segments (n=11) placed in this condition 
were slightly longer, ranging from 5-9cm. The veins were preserved in 1.2L of 
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UW with 5%,10% or 20% HPL for 7 days (5% HPL) or 14 days (5%, 10% or 20% 
HPL).  
The Lifeport system is a temperature dependent, pressure-based system. By 
setting a certain pressure, a desired resistance is acquired that maintains the set 
pressure. If resistance in the veins is too high, the system will shut down. If flow 
in the segments exceeds 200ml/min due to a lack of resistance and inability to 
reach the desired pressure, the system will shut down. Perfusion pressures were 
initially set lower, obtaining a flow rate of around 150ml/min. Later experiments 
were run at higher pressures to obtain a flow rate of 50 ml/min. Table B shows 
averages of flow and pressure for the Lifeport samples. Perfusion pressures 
ranged from 2 – 12 mmHg, corresponding to 1-5 dynes/cm2 shear stress, which 
is within the low normal range of shear stress in venous circulation (23).  
In order to maintain a pressure around 12 mmHg and a flow of 50ml/min, 
different sized male barbed tips were tested ranging from 1/16” to 1/4” in 
diameter. Tying a 1/16” tip to the distal end of the vein maintained the desired 
pressure and flow in the Lifeport.  
Ice was changed in the system up to twice daily to maintain the temperature 
around 4°C and no higher than 8°C. If temperature rose above 8°C, the system 
shut off and had to be cooled to 4-6°C before starting flow again.  
Samples in the Lifeport were preserved for either 7 days or 14 days. For 7-day 
culture, 0.5-1cm segments were collected from the middle of the veins at Day 7 
and placed in either 4% PFA or 10% formalin, SEM fixative, and RNALater 
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(Thermo Fisher Scientific, Waltham, MA) for RNA quantification. RNA samples 
were flash frozen in liquid nitrogen and stored at -80°C. For 14-day culture, 
samples were collected at Day 3, 7, 10 and 14 for histological, SEM and RNA 
evaluation.  
 
  Figure 5. Lifeport setup (23)    Figure 6. Lifeport culture (23) 
 
 
 
 
 
 
Table B. Lifeport Data Summary 
Vein 
Avg. pressure 
(mmHg) 
Avg. Flow 
(ml/min per 
vein) 
1 10 165 
2 11 149 
3 12 112 
4 11 56 
5 9 75 
6 12 53 
7 11 63 
8 11 50 
9 9 48 
10 11 76 
11 11 78 
 
 
	 16	
Flow Preservation: BioRx 2 
Lastly, a second bioreactor (BioRx 2) was designed to mimic the flow in the 
Lifeport system (Figure 7). The same roller pump was utilized to create flow in 
the veins. Pump settings were calibrated with the new BioRx 2 setup to achieve a 
flow of 50ml/min per vein. 1/16” tips were tied at the end of the veins to achieve a 
desired pressure of 12mmHg. Flow segments in BioRx 2 (n=9) ranged from 4 – 7 
cm (Figure 8). Samples in BioRx 2 were preserved for 14 days. At time points 
Day 3, 7, 10, and 14, 0.5-1cm segments were collected and placed in 4% PFA, 
SEM fixative, and RNALater. ~5mL of media was collected for later metabolite 
testing. Media samples were stored at -80°C.  
 
 Figure 7. BioRx 2 setup           Figure 8. BioRx 2 culture 
           
 
 
Flow sample totals are summarized in Table C.  
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Table C. Flow Sample Totals 
Flow Culture BioRx 1 Lifeport BioRx 2 
Total veins 22 11 3 
Total segments 57 13 9 
7-day culture 57 9 0 
14-day culture 0 4 9 
 
Acute samples were compared to end point static or flow samples. Static and 
flow samples were analyzed in burst pressure testing, histopathological 
evaluation, platelet adhesion tests, shear stress testing (flow only), scanning 
electron microscopy and RNA quantification (flow only). To date, 14-day flow 
samples have only been analyzed with histopathological evaluation.  
  
V. Verification Study  
 
 
For pre-clinical testing, verification veins (n=6) were collected and cultured in the 
Lifeport for 7 days to solidify previous flow preservation results and confirm that 
preservation methods were infection-free. Clinical grade penicillin (WG Critical 
Care, Paramus, NJ), amphotericin (X Gen Pharmaceuticals Inc., Big Flats, NY), 
UW solution (Organ Recovery Systems, Itasca, IL) and HPL (Compass 
Biomedical, Hopkinton, MA) were used (23). Umbilical cords were collected from 
cesarean section deliveries to ensure sterility, immediately placed in UW solution 
with antibiotics and stored at 4°C. Umbilical veins were dissected from the cords 
in a sterile room adjacent to the operating room in order to ensure minimal time 
between delivery and culture. Vein segments were placed in the Lifeport with UW 
plus 5% HPL for 7 days at 4°C. Lifeport pressures ranged from 10-12mmHg at 
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flow rates between 31-63 ml/min (23). 1cm segments were collected from the 
middle of the veins at Day 0 (fresh) and Day 7 (flow) and fixed in 4% PFA for 
histological evaluation. Samples of media were collected at Day 0 and Day 7 
(n=6) and sent for microbiology testing (Boston Children’s Hospital clinical 
microbiology lab) for aerobic, anaerobic and fungal culture (23). At end point Day 
7, ~2mL of media (n=3) was collected and sent for mycoplasma testing (WuXi 
AppTec, Philadelphia, PA).  
 
VI. 7-Day Culture versus 14-Day Culture 
 
 
7-day and 14-day cultures were tested for both static and flow conditions. The 
static culture was set up the same way as previously described. 7-day static 
samples were fixed in OCT, 10% formalin or 4% PFA and SEM fixative for 
histopathological and SEM evaluation. 14-day static samples were fixed in OCT, 
10% formalin or 4% PFA and analyzed with histopathological evaluation.  
For the flow conditions, BioRx 1 and the Lifeport were used for 7-day culture, 
whereas BioRx 2 and the Lifeport were used for 14-day studies. For 14-day 
culture, after dissection of the vein and collection of fresh samples, the remaining 
segments were placed in BioRx 2 or the Lifeport with either UW + 5% HPL (n=8), 
UW + 10% HPL (n=3) or UW+ 20% HPL (n=3). 0.5 - 1 cm segments of preserved 
umbilical vein were collected at time points Day 3, Day 7, Day 10 and Day 14 for 
histopathological evaluation, RNA quantification and SEM. Media samples 
(~5mL) were also collected at each time point for later metabolite testing in order 
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to observe growth factor depletion and the decline of endothelial viability. 
Samples (n=6) from the same vein (n=2) have been tested in the Lifeport and 
BioRx 2 system simultaneously. For this culture, two-thirds of media (UW + 5% 
or 10% HPL) in the Lifeport was exchanged at time point Day 7 in order to 
evaluate differences in endothelium at Day 14 compared to flow samples without 
a media change. Day 7 media sample was collected prior to exchanging the 
media. 
 
VII. Burst Pressure  
 
 
Burst pressure testing was utilized to determine the strength of the veins to 
ensure their ability to withstand physiological pressures. A burst pressure stand 
was developed (Figure 9) and used to test fresh (n=11) veins, veins with one 
week of preservation (n=8) and veins with two weeks of preservation (n=16). 
Saline was used to initially fill the veins, and baseline pressure was recorded. 
The veins were then pressurized with saline until failure, and pressure was 
recorded.  
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 Figure 9. Burst pressure stand setup 
 
 
 
 
 
VIII. Histopathological Evaluation 
 
 
OCT or 4% PFA / 10% formalin samples of fresh, static and flow veins were 
submitted to the Pathology Core at Brigham and Women’s Hospital (Boston, MA) 
for histopathological evaluation. Fresh (n=9), static (n=14) and flow (n=18) 
samples had adjacent OCT and 4% PFA/ 10% formalin samples. Frozen OCT 
samples were mounted and sectioned at 7um. Frozen samples were stained for 
H&E, ICAM-1, VCAM-1, von Willebrand Factor (vWF), alpha smooth muscle 
actin (a-SMA) and endothelial nitric oxide synthase (eNOS). 4% PFA or 10% 
formalin samples were embedded in paraffin. Paraffin samples were stained for 
Hematoxylin & Eosin (H&E), CD31 and Movat pentachrome (Movat). H&E was 
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used to observe overall morphology of the veins, Movat helped to visualize 
extracellular matrix components, and the endothelium was visualized with 
immunohistochemistry (23).  
Verification vein samples were fixed in 4% PFA, embedded in paraffin and 
stained for H&E, Masson’s Trichrome, a-SMA and CD31.  
14-day flow samples did not have frozen sections. Samples were fixed in 4% 
PFA, embedded in paraffin and stained for H&E, vWF and CD31. 
 
Table D summarizes stain descriptions.  
 
Table D. Histological and IHC stain descriptions 
 
Stain Function 
H&E 
General stain to observe tissue morphology.  
Hematoxylin- stains nucleic acids blue 
Eosin- stains extracellular matrix and cytoplasm pink  
(32) 
CD31 
Stains for CD31, which is an endothelial marker. CD31 is localized at 
endothelial cell junctions and plays a role in the adhesion of endothelial cells 
to one another and inflammatory cells to the endothelium (33,34).  
Movat  
Stains for 5 components in the ECM: 
Nuclei/elastin- black 
Collagen/reticular fibers- yellow 
Ground substance/mucin- blue 
Fibrin- bright red 
Muscle- red  
(35) 
vWF 
Stains for vWF, which is stored in endothelial cells. vWF is released upon 
vascular damage and has a role in hemostasis (36,37).  
eNOS 
Stains for eNOS, which produces nitric oxide (NO). NO is a relaxing factor for 
smooth muscle cells in vasculature (38).  
ICAM-1/ VCAM-1 
ICAM-1: intercellular adhesion molecule 
VCAM-1: vascular adhesion molecule  
ICAM-1 and VCAM-1 aid in adhesion and transendothelial migration of 
inflammatory cells (39).  
a-SMA 
Stains smooth muscle cells (SMC) and myofibroblasts; a-SMA is an isoform 
of typical smooth muscle cells and is present in high amounts in vascular 
SMC (40,41).  
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Masson's 
Stains for 3 components in the ECM: 
Nuclei- deep blue 
Skeletal and smooth muscle- red 
Collagen and mucin- blue 
(35) 
 
 
IX. Platelet Adhesion 
 
 
Fresh (n=2), 7-day static (n=4) and 7-day flow (n=7) samples were tested for 
endothelial injury indicated by platelet adhesion. A thin bovine collagen scaffold 
(DSM Biomedical, Exton, PA) (n=5) was used as a positive control. Whole sheep 
blood Na-Heparin (Lampire Biological Labratories, Pipersville, PA) was warmed 
to 37°C in an incubator, and 0.0047g/L of quinacrine dihydrochloride (mepacrine) 
was mixed with the blood for 30 minutes on a stir plate in order to fluorescently 
label the platelets. Mepacrine does not alter the function of platelets (42,43). 7-
day static, 7-day flow samples and the collagen tubes were placed in BioRx 1 
and warmed to 37°C in an incubator. The media was pumped out and replaced 
with the blood and mepacrine mixture, which was subsequently pumped through 
the samples for 30 minutes at flows of 150 ml/min/vein that corresponded to ~5 
dynes/cm2 shear stress. After testing the samples were sliced open 
longitudinally, rinsed gently with saline and placed endothelium-down in a culture 
dish (Figures 10 and 11). The endothelium was visualized using fluorescence 
with a 488nm filter and Axio Observer Z1 inverted microscope (Carl Zeiss, Jena, 
Germany). Platelets were counted and averaged over six high power fields per 
sample and compared in control, 7-day static and 7-day flow samples. 
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  Figure 10. Platelet adhesion vein sample Figure 11. Platelet adhesion collagen control   
 
 
 
 
X. Shear Stress  
 
 
Shear stress testing was developed to mimic the physiological shear forces the 
veins would experience upon implantation. After preservation under flow 
conditions in BioRx 1 for 7 days, segments of umbilical vein (n=3) were stented 
down to 3mm and placed in BioRx 1 (Figure 12). Whole sheep blood Na-Heparin 
was pumped through the stented veins for 15 minutes at flows of 200ml/min/vein 
that corresponded to ~7 dynes/cm2 shear stress. After the test, 0.5cm - 1cm 
sections of the stented and unstented vein were collected for histopathological 
evaluation including H&E, CD31 and Movat, and for SEM. 
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           Figure 12. Shear stress setup 
 
 
 
 
XI. Scanning Electron Microscopy 
 
 
Fresh (n=2), static (n=5) and flow (n=6) samples collected for SEM evaluation 
were placed in a fixative composed of 3% PFA, 2% glutaraldehyde, and 5% 
sucrose in 0.1M sodium cacodylate buffer. After at least 24 hours sitting in the 
fixative, umbilical vein samples were sliced open, and a piece of the endothelium 
was obtained with a 5mm punch. If the original samples were big enough, more 
than one 5mm section was collected. If the original samples were smaller than 
5mm diameter, they were only sliced open if necessary. Samples were then 
dehydrated in series in 50%, 75%, 90%, 95% ethanol for 15 minutes in each 
dilution. Lastly, the samples were dehydrated for three more cycles of 15 minutes 
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in fresh 100% ethanol and then stored in 100% ethanol until further preparation 
for imaging. After dehydration, samples were placed in a Critical Point Drier 
(Autosamdri-815, Tousimus, Rockville, MD) for ~3 hours. Samples were mounted 
on imaging pedestals, sputter coated with Gold/Palladium (Hummer 6.2 sputter 
coater, Anatech, Union City, CA) and then imaged on a JEOL 5600LV scanning 
electron microscope (JEOL USA, Peabody, MA).  
 
XII. Statistical Methods 
 
Values for vein diameter, vein length and burst pressure are expressed in mean 
± standard deviation. Mean values of platelet counts were analyzed by Student’s 
t test. P values <0.05 were considered statistically significant (23).  
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RESULTS 
 
I. Burst Pressure 
 
There was no difference in burst pressure between fresh umbilical veins (n=16) 
and veins preserved for either 7 days (n=8) or 14 days in static or flow conditions 
(n=11) (431 ± 229 mmHg vs. 419 ± 128 mmHg vs. 438 ±  244 mmHg 
respectively).  
 
II. Media 
 
EBM plus FBS in static culture and EBM plus HPL in static or flow culture 
demonstrated inadequate preservation of endothelium with endothelial and 
medial separation and breakdown (not shown). Veins preserved statically in plain 
UW showed similar results with evidence of necrosis in the medial layer and 
breakdown of the endothelium (not shown) (23).  
Both static and flow culture utilizing UW with HPL resulted in preserved 
endothelium and vascular wall based on the following histopathological results.   
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III. Static Preservation versus Flow Preservation 
 
Histopathological Evaluation 
 
H&E and Movat for fresh, 7-day static and 7-day flow samples preserved in UW 
plus 5% HPL are shown in Figure 13. Based on H&E, flow samples exhibited 
overall improved morphology of the endothelial and medial layers compared to 
static samples. Movat staining clearly demonstrates preservation of the 
extracellular matrix of both static and flow samples, including a strong staining for 
glycosaminoglycans (GAGs) in green/blue and collagen in yellow (23). Both 
static and flow samples had confluent internal elastic lamina as seen in black, 
although it appeared more defined in the flow samples (23).  
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Figure 13. H&E (A-F) and Movat (G-I) staining (23). Fresh: A, D, G. 7-day Static: B, 
E, H. 7-day Flow: C, F, I. scale bar= 250um; * denotes lumen.  
 
 
CD31 and vWF stains for fresh, 7-day static and 7-day flow samples are shown 
in Figure 14. CD31 was present in all samples, but was more confluent among 
fresh and 7-day flow samples compared to 7-day static samples. vWF varies little 
from fresh to 7-day static and 7-day flow samples. The presence of vWF in HPL 
may account for the uniform staining of vWF in both static and flow veins (23).  
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Figure 14. CD31 (A-F) and vWF (G-I) staining (23). Fresh: A, D, G. 7-day Static: B, 
E, H. 7-day Flow: C, F, I. Scale bar= 250um; * denotes lumen.  
 
eNOS (Figure 15) was not initially confluent throughout the endothelium of fresh 
samples. 7-day static and 7-day flow samples demonstrate a similar expression.  
ICAM-1 and VCAM-1 were negative in flow samples compared to static ones, 
indicating that endothelial cells were not activated due to injury (Figure 15).  
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Figure 15. eNOS (top row), ICAM-1 (middle row), VCAM-1 (bottom row) (23). Fresh: 
left column. 7-day Static: middle column. 7-day Flow: right column. Scale bar= 
250um.  
 
 
Platelet Adhesion 
 
Figure 16 includes a graph of the number of platelets counted in collagen 
control, 7-day static, 7-day flow samples. In Figure 17, collagen samples (A-C) 
show high amounts of platelet attachment, while the static (D-F) and flow 
samples (G-I) have significantly less platelet attachment. However, flow samples 
had significantly less platelet attachment than static samples. Lower counts of 
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platelets in flow samples demonstrate less endothelial injury compared to static 
samples.  
 
 Figure 16. Platelet Counts. p value between static and flow <0.01 
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Figure 17. Platelet Adhesion (23). Collagen control: A-C. 7-day Static: D-F. 7-day 
Flow: G-I. Scale bar= 500um.  
 
 
 
 
 
 
 
SEM 
 
 
Scanning electron microscopy helped to visualize overall cell morphology and 
alignment in umbilical vein endothelium. Fresh samples demonstrate an intact 
endothelium with flow-aligned cells. The 7-day flow samples show similar results 
of flow aligned cells and consistent endothelium without basement membrane 
exposure. The 7-day static samples do not demonstrate endothelial cell flow 
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alignment, but instead have a cobblestone appearance with breaks in the 
endothelium and exposed basement membrane (23). Image 18 compares fresh 
(A, D), static (B, E), and flow samples (C, F).  
 
Image 18. SEM analysis (23). Fresh: A, D. 7-day Static: B, E. 7-day Flow: C, F.  
 
IV. Verification Study 
 
Microbiological testing (n=6) and micoplasma testing (n=3) were negative at the 
time of preservation and after 7 days of preservation. Histological evaluation of 
verification veins confirmed previous results for flow-preservation samples for 7 
days at 4°C. H&E and Masson’s Trichrome showed an intact ECM similar to 
previous flow samples in Figure 13 (23). Robust a-SMA staining in fresh and 7-
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day flow verification veins demonstrated exceptional preservation of the vascular 
wall (Figure 19) (23). CD31 results for 7-day flow verification samples exhibited 
an intact endothelium similar to that of the fresh verification samples (Figure 19) 
(23).  
 
Image 19. Verification samples: a-SMA (A, B) and CD31 (C, D) with DAPI 
counterstain (23). Fresh: A, C. 7-day Flow: B, D. scale bar= 50um.  
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V. 7-day Culture versus 14-day Culture 
 
Preliminary results of 14-day culture studies of UW plus 5% HPL without a media 
change at Day 7 show well-preserved morphology in Days 3, 7, 10 and 14 
samples indicated by H&E. CD31 was present throughout all samples, but not as 
confluent in the Day 10 and 14 samples. Day 10 and Day 14 samples were 
negative for a-SMA, indicating break down of the smooth muscle layer of the 
vessel. Later results will demonstrate the effects of higher HPL concentrations 
and a media change at Day 7.  
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DISCUSSION 
 
This study was performed in order to optimize preservation of umbilical 
veins for use as autologous BT shunts in neonatal cardiac reconstruction. Overall 
results showed that veins preserved under the flow condition maintained 
endothelial integrity and function.  
Even with rigorous anticoagulative therapies postoperatively, thrombosis 
and stenosis of the BT shunt still occur in 3-12% of patients undergoing this 
procedure (1,5). With thrombosis and stenosis cited as major factors contributing 
to high morbidity and mortality rates associated with BT shunts (5), a solution to 
decrease coagulability of the shunt needs to be addressed. Preserved 
autologous umbilical vein grafts may be a feasible replacement to alleviate the 
thrombotic and stenotic risks of the current PTFE grafts primarily due to a 
preserved endothelium. This study demonstrates that collecting, dissecting and 
preserving umbilical veins stands as a practical option to improve outcomes in 
patients receiving BT shunts as part of their neonatal repair. This is due to 
advances in fetal ultrasound technology, the availability of sufficient length of 
umbilical cord at birth and the adaptability of the diameter of veins for a BT shunt 
(23).  
Warm preservation was first tested, but proved inadequate. Cold 
preservation was subsequently tested based on previous results showing that 
cold preservation (0-4°C) extends the length of preservation (44). Current organ 
	 37	
preservation of livers and kidneys utilize cold storage, with or without perfusion 
(21). Since UW solution is the most common organ preservation solution for 
kidneys, livers and pancreases (24), it was adopted in this study. Due to 
concerns with immune reactions to FBS, which is an animal-based serum, HPL 
stands as a suitable human and clinical substitute. UW plus 5% HPL with flow 
preservation adequately preserved function and morphology of umbilical vein 
endothelium and vascular wall based on histological, platelet adhesion, and SEM 
testing.  
Burst pressure tests indicate that umbilical veins do not lose strength after 
being cultured for up to two weeks either in static or flow conditions, verifying that 
preserved umbilical veins can withstand physiological pressures. Although 
overall 7-day flow samples had improved morphological appearance compared 
to static 7-day samples as seen with H&E, static and flow samples had 
qualitatively similar appearances in Movat, CD31, vWF, eNOS and ICAM-1/ V-
CAM-1. Both static and flow segments displayed CD31 staining of the 
endothelium, but fresh and flow samples showed more uniform staining 
compared to static samples. Stronger CD31 in flow samples demonstrates that 
flow culture better preserves junctions between endothelial cells as well as their 
ability to react properly in an inflammatory state. Both static and flow samples 
had well-preserved ECM preservation as noted by positive staining of the internal 
elastic lamina and glucosaminoglycans at 7 days. The internal elastic lamina 
appeared to have a stronger presence in flow samples. Elastin in vascular walls 
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helps to accommodate volume fluctuations and its preservation would be 
necessary in umbilical veins utilized in cardiac repair. vWF, an endothelial cell 
marker, was uniform in both static and flow samples, but could perhaps be 
attributed to the presence of vWF in HPL. eNOS expression for static and flow 
samples were similar in appearance and did not significantly differ from the fresh 
samples. Lastly, ICAM-1 and VCAM-1 were negative in fresh, static and flow 
samples, indicating an inactive endothelium due to little injury. Without injury, 
endothelial cells remain un-activated or quiescent, thus promoting an 
antithrombotic surface (45).  
Platelet adhesion testing and SEM imaging helped to distinguish static 
versus flow preservation techniques. Flow samples had reduced endothelial 
injury compared to static samples when evaluated in platelet attachment, 
suggesting that flow conditions maintain the presence and function of the 
endothelial wall and reduce injury compared to static preservation. SEM for flow 
samples showed intact endothelium with flow-aligned cells. Static samples 
contained breaks in the endothelium without flow-aligned cells, indicating 
breakdown of the endothelium in static preservation.  
This study demonstrated preservation of endothelium of umbilical veins for 
up to 7 days, but many neonatal surgeries occur beyond 7 days. Thus the next 
steps in our study will determine the parameters necessary to lengthening 
preservation up to 14 days. 14-day studies have been implemented in order to 
determine the decline of endothelial and medial viability in the umbilical veins, 
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observe growth factor depletion in a longer culture, as well as optimize the 
concentration of HPL based on these results. Collecting and analyzing samples 
at frequent time points during the 14-day cultures will help to track the precise 
decline of endothelial function and integrity over the two-week period. Paralleling 
14-day culture with varying HPL concentrations (5%, 10%, 20%) will help to 
determine if and how HPL concentrations decelerate endothelial decline. By 
running segments from the same vein in BioRx 2 and the Lifeport (with a 2/3 
media change at Day 7 for Lifeport only), growth factor depletion and metabolite 
production can be observed. With more experiments performed and data 
collected, the optimal time and HPL concentration for flow preservation of 
umbilical veins can be effectively determined. 
 Additionally, the shear stress tolerance of umbilical veins needs to be 
further evaluated. By stenting down part of an umbilical vein after flow culture, 
physiological scenarios can be mimicked in order to determine the viability of the 
endothelium with exposure to physiological shear stress. The vein samples 
should be cultured for 7 and 14 days prior to shear stress testing in order further 
verify the optimal length of preservation prior to implantation.  
Overall this study was implemented to determine optimal preservation of 
autologous umbilical vein segments for use as BT shunts in neonatal cardiac 
repair. Results show that flow preservation with UW plus 5% HPL adequately 
preserves the umbilical vein endothelium, thus demonstrating the viability of 
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utilizing preserved autologous umbilical vein grafts at BT shunts in order to 
reduce the risks of thrombosis and stenosis inherent to the current PTFE graft.  
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